Gyre Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders voted on four key proposals, all of which received sufficient support to pass. No questions were raised, and the meeting concluded with confirmation that final vote results will be filed with the SEC.
Fiscal Year 2025
-
A leading fibrosis-focused pharma maintains dominant market share in China, with a robust pipeline led by hydronidone, which showed strong Phase 3 results for CHB and is advancing toward U.S. trials for MASH. Strategic acquisitions and integrated operations support global expansion.
Fiscal Year 2024
-
The conference highlighted a robust anti-fibrotic pipeline, with Hydronidone showing promising efficacy and safety in liver fibrosis. Phase 3 results are expected in early 2025, and combination strategies are being explored to further enhance outcomes.
-
The company is advancing anti-fibrotic therapies, with three commercial drugs and a lead candidate, F351, in phase III for HBV-associated liver fibrosis, expecting results in early 2025. Expansion into the US and global markets is planned, with a diversified pipeline targeting chronic inflammation.
-
Three approved drugs and a robust pipeline position the company as a leader in anti-fibrotic therapies, with F351 pivotal trial results expected in early 2025. U.S. expansion and new indications are planned, supported by strong China sales and ongoing profitability.